Recro Gainesville Adds New Facility

Recro Gainesville has added a 24,000-sq.-ft. facility, which includes high-potent material processing space, near its existing 97,000- sq.-ft. contract development and manufacturing plant. The company is a wholly owned subsidiary of Recro Pharma, Inc., and a provider of pharmaceutical solid oral dose development and manufacturing services.
 
The expanded capabilities will allow Recro Gainesville to provide a broader range of services from formulation and development through clinical trial material (CTM) production for Phase I and beyond.
 
In addition, a specialized area within the new site will be opened by the end of the year to support clients with development through commercialization for high-potency compounds, a growing category of pharmaceuticals, which includes many immune modulation and anti-cancer agents.
 
"The new square footage allows for early feasibility studies, enabling clients to quickly determine the best formulation path forward at laboratory scale, and subsequent scale-up to the GMP manufacture of CTMs," said Scott Rizzo, general manager of Recro Gainesville. "This added development capability will save our clients both time and resources." 

-------------------------------------------------

Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.